Market capitalization | $401.85m |
Enterprise Value | $109.63m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 10.83 |
P/S ratio (TTM) P/S ratio | 39.71 |
P/B ratio (TTM) P/B ratio | 0.94 |
Revenue growth (TTM) Revenue growth | 496.00% |
Revenue (TTM) Revenue | $10.12m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
11 Analysts have issued a Autolus Therapeutics plc forecast:
11 Analysts have issued a Autolus Therapeutics plc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 10 10 |
495%
495%
|
|
Gross Profit | -8.98 -8.98 |
84%
84%
|
|
EBITDA | -233 -233 |
38%
38%
|
EBIT (Operating Income) EBIT | -241 -241 |
37%
37%
|
Net Profit | -221 -221 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Head office | United Kingdom |
CEO | Christian Itin |
Employees | 647 |
Founded | 2014 |
Website | www.autolus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.